This article has been updated to include comments from Affymetrix.

The strong demand Illumina has seen for its family of exome arrays apparently took the company by surprise, an Illumina executive said last week.

Moreover, the firm now believes that the majority of projects run on its BeadChips will move to focused arrays, such as its exome chips, and away from the genome-wide screening tools that have been popular in the past, said Christian Henry, general manager of Illumina's genomic solutions business.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.